Compare ARK Genomic Revolution ETF (ARKG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Recursion Pharmaceuticals Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Recursion Pharmaceuticals Inc trades at $3.51 (market cap $1.89B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $6.79 |
52-Week Low | $23.09 | $2.84 |
Market Cap | — | $1.89B |
Enterprise Value | — | $1.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
RXRX trades at $3.56, down 5.32% today, with a bullish technical signal from moving averages but concerning fundamentals. The company shows deep losses with a -851.51% net income margin and negative cash flow from operations, though it has beaten earnings estimates for three consecutive quarters. Analyst consensus is mixed with a $7.83 price target representing significant upside potential from current levels.
While technical indicators suggest near-term strength and analyst targets imply 120% upside, RXRX faces substantial execution risks as a pre-revenue biotech. The company's AI-driven drug discovery platform shows promise but requires successful clinical outcomes to justify its valuation. High cash burn and negative profitability metrics present significant challenges for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
